{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:47:40Z","timestamp":1791848860908,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007048","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.mayocp.2024.12.013","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T09:14:56Z","timestamp":1743066896000},"page":"954-961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety of Acamprosate in Patients With Alcohol-Associated Liver Disease: A Single-Arm Phase 2 Trial"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7588-4312","authenticated-orcid":false,"given":"Tiffany","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Y.","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasha","family":"Kulai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cori","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Olofson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timucin","family":"Taner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4095-8144","authenticated-orcid":false,"given":"Douglas A.","family":"Simonetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mayocp.2024.12.013_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Sepanlou","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.mayocp.2024.12.013_bib2","doi-asserted-by":"crossref","first-page":"e2213014","DOI":"10.1001\/jamanetworkopen.2022.13014","article-title":"Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder","volume":"5","author":"Vannier","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.mayocp.2024.12.013_bib3","doi-asserted-by":"crossref","first-page":"e0093","DOI":"10.1097\/HC9.0000000000000093","article-title":"Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis","volume":"7","author":"Rabiee","year":"2023","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.mayocp.2024.12.013_bib4","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.31042","article-title":"Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis","volume":"71","author":"Rogal","year":"2020","journal-title":"Hepatology"},{"issue":"9603","key":"10.1016\/j.mayocp.2024.12.013_bib5","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.mayocp.2024.12.013_bib6","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2174\/138161211796150765","article-title":"Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review","volume":"17","author":"Edwards","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.mayocp.2024.12.013_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8835647","article-title":"Disulfiram-induced acute liver injury","volume":"2020","author":"Ramer","year":"2020","journal-title":"Case Reports Hepatol"},{"issue":"4","key":"10.1016\/j.mayocp.2024.12.013_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/clpt.1985.197","article-title":"Effects of long-term therapy with naltrexone on body weight in obesity","volume":"38","author":"Atkinson","year":"1985","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.mayocp.2024.12.013_bib9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1530-0277.2007.00593.x","article-title":"Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics","volume":"32","author":"Lucey","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"issue":"12","key":"10.1016\/j.mayocp.2024.12.013_bib10","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/hep4.2080","article-title":"Naltrexone for alcohol use disorder: hepatic safety in patients with and without liver disease","volume":"6","author":"Ayyala","year":"2022","journal-title":"Hepatol Commun"},{"issue":"18","key":"10.1016\/j.mayocp.2024.12.013_bib11","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.mayocp.2024.12.013_bib12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MEG.0000000000002304","article-title":"Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice","volume":"34","author":"Tyson","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.mayocp.2024.12.013_bib13","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-015-0423-9","article-title":"Acamprosate: a review of its use in alcohol dependence","volume":"75","author":"Plosker","year":"2015","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.mayocp.2024.12.013_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4088\/JCP.13m08940","article-title":"Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study)","volume":"76","author":"Higuchi","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.mayocp.2024.12.013_bib15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/JCP.0000000000000590","article-title":"Anterior cingulate glutamate is reduced by acamprosate treatment in patients with alcohol dependence","volume":"36","author":"Frye","year":"2016","journal-title":"J Clin Psychopharmacol"},{"issue":"8-9","key":"10.1016\/j.mayocp.2024.12.013_bib16","first-page":"687","article-title":"Effect of acute administration of acamprosate on the risk of hepatic encephalopathy and on blood pressure in alcoholic cirrhotic patients","volume":"16","author":"Delgrange","year":"1992","journal-title":"Gastroenterol Clin Biol"},{"issue":"2","key":"10.1016\/j.mayocp.2024.12.013_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cgh.2019.04.048","article-title":"Alcohol rehabilitation within 30 days of hospital discharge is associated with reduced readmission, relapse, and death in patients with alcoholic hepatitis","volume":"18","author":"Peeraphatdit","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.mayocp.2024.12.013_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ijcp.12764","article-title":"Pharmacotherapy of alcoholic liver disease in clinical practice","volume":"70","author":"Rosato","year":"2016","journal-title":"Int J Clin Pract"},{"issue":"8","key":"10.1016\/j.mayocp.2024.12.013_bib19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/apt.17665","article-title":"Systematic review: interventions for alcohol use disorder in patients with cirrhosis or alcohol-associated hepatitis","volume":"58","author":"Oldroyd","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.mayocp.2024.12.013_bib20","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/HEP.0000000000000570","article-title":"Medications for alcohol use disorder promote abstinence in alcohol-related cirrhosis: results from a systematic review and meta-analysis","volume":"79","author":"Gratac\u00f3s-Gin\u00e8s","year":"2024","journal-title":"Hepatology"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619624006864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619624006864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:40:39Z","timestamp":1762213239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619624006864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0025619624006864"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2024.12.013","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of Acamprosate in Patients With Alcohol-Associated Liver Disease: A Single-Arm Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2024.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}